Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024

<< Previous

Bullboard Posts

Next >>

Comment by pelabooston Dec 30, 2023 11:17am

188 Views

Post# 35805089

RE:Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024

@askretka. If Andrus Reo is involved, it should be noted that Andrus is a Russian biotech that was at least in part funded by a Russian government biotech fund. Between Andrus, Anson and no abstract one can one can only surmise that this is getting curiouser and curiouser.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China